EMERYVILLE, Calif., Oct. 11,
2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a
leading synthetic biotechnology company accelerating the world's
transition to sustainable consumption through its
Lab-to-Market™ technology platform and clean beauty consumer
brands, today announced that three of its consumer brands will be
included in Sephora's launch in the United Kingdom (UK).
When Sephora launches its UK website on October 17th, three Amyris brands –
Biossance, JVN Hair and Rose Inc – will be available on Sephora
UK's website. In addition, Biossance and JVN will be available at
the flagship brick and mortar store in London, opening March
2023.
This expansion of Amyris' brands in the UK is the latest step in
its global partnership with Sephora and further evidence of Amyris'
growth around the globe. Amyris was recently recognized by Women's
Wear Daily (WWD) as the leading small cap beauty company in the
world due to its execution on what consumers are seeking in clean,
sustainable products that deliver best-in-class performance.
Today, consumers in the UK already enjoy access to Amyris
consumer brands sold in SpaceNK, Selfridges, Harrods, Cult Beauty,
and will also be able to access Amyris' brands via their
direct-to-consumer brand websites in the coming months. Amyris
plans to expand its offering in the UK and Europe with additional brands and retail store
presence during 2023.
"Amyris consumer brands are delivering some of the best
performance in health and beauty and are accelerating on the back
of significant consumer demand across the critical global markets
for clean, sustainable health and beauty products at an accessible
price," said John Melo, President
and Chief Executive Officer. "We are executing very well, and our
revenue has continued to grow sequentially. Consumers are doubling
down on clean beauty. Along with some of the strongest growth
across the beauty industry for our ingredients and consumer
business, we are making great progress on lowering our costs with
"Fit to Win," designed to deliver operational excellence. We are
pleased with the closing of our short-term financing that we
announced this morning and are set for an excellent finish to
2022."
About Amyris
Amyris (Nasdaq: AMRS) is a leading synthetic biotechnology company,
transitioning the Clean Health & Beauty and Flavors &
Fragrances markets to sustainable ingredients through fermentation
and the company's proprietary Lab-to-Market™ technology
platform. This Amyris platform leverages state-of-the-art machine
learning, robotics and artificial intelligence, enabling the
company to rapidly bring new innovation to market at commercial
scale. Amyris ingredients are included in over 20,000 products from
the world's top brands, reaching more than 300 million consumers.
Amyris also owns and operates a family of consumer brands that is
constantly evolving to meet the growing demand for sustainable,
effective and accessible products. For more information, please
visit http://www.amyris.com.
Amyris, the Amyris logo, and Lab-to-Market, are trademarks or
registered trademarks of Amyris, Inc. or its subsidiaries in the
U.S. and/or other countries.
Forward-Looking
Statements
This release contains forward-looking statements, and any
statements other than statements of historical fact could be deemed
to be forward-looking statements. These forward-looking statements
include, among other things, statements regarding future events,
such as Amyris' inclusion in Sephora's UK launch; and Amyris'
expectations about the expansion of its brands in the UK, the
acceleration of consumer revenue and lowering of operating costs,
and performance for the remainder of the year 2022. These
statements are based on management's current expectations and
actual results and future events may differ materially due to risks
and uncertainties, including risks related to Amyris' liquidity and
ability to fund operating and capital expenses, risks related to
its financing activities, risks related to potential delays or
failures in completing and integrating planned acquisitions, risks
related to potential delays or failures in development, regulatory
approval, launch, production and commercialization of products,
risks related to the COVID-19 pandemic and any other geopolitical
events, including Russia's invasion of Ukraine,
resulting in global economic, financial and supply chain
disruptions that may negatively impact Amyris' business operations
and financial results or cause market volatility, risks related to
Amyris' reliance on third parties particularly in the supply chain,
and other risks detailed from time to time in filings Amyris makes
with the Securities and Exchange Commission, including Annual
Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current
Reports on Form 8-K. Amyris disclaims any obligation to update
information contained in these forward-looking
statements, whether as a result of new information, future events,
or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/amyris-brands-expanding-in-uk-and-europe-executing-on-continued-accelerated-growth-and-lower-costs-301645977.html
SOURCE Amyris, Inc.